BIOMAT Database Logo BIOMAT Database Logo

Infliximab maintenance therapy for fistulizing Crohn's disease. 2004

Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA.

BACKGROUND Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It is not known whether infliximab is an effective maintenance therapy for patients with fistulas. METHODS We performed a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of infliximab maintenance therapy in 306 adult patients with Crohn's disease and one or more draining abdominal or perianal fistulas of at least three months' duration. Patients received 5 mg of infliximab per kilogram of body weight intravenously on weeks 0, 2, and 6. A total of 195 patients who had a response at weeks 10 and 14 and 87 patients who had no response were then randomly assigned to receive placebo or 5 mg of infliximab per kilogram every eight weeks and to be followed to week 54. The primary analysis was the time to the loss of response among patients who had a response at week 14 and underwent randomization. RESULTS The time to loss of response was significantly longer for patients who received infliximab maintenance therapy than for those who received placebo maintenance (more than 40 weeks vs. 14 weeks, P<0.001). At week 54, 19 percent of patients in the placebo maintenance group had a complete absence of draining fistulas, as compared with 36 percent of patients in the infliximab maintenance group (P=0.009). CONCLUSIONS Patients with fistulizing Crohn's disease who have a response to induction therapy with infliximab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007412 Intestinal Fistula An abnormal anatomical passage between the INTESTINE, and another segment of the intestine or other organs. External intestinal fistula is connected to the SKIN (enterocutaneous fistula). Internal intestinal fistula can be connected to a number of organs, such as STOMACH (gastrocolic fistula), the BILIARY TRACT (cholecystoduodenal fistula), or the URINARY BLADDER of the URINARY TRACT (colovesical fistula). Risk factors include inflammatory processes, cancer, radiation treatment, and surgical misadventures (MEDICAL ERRORS). Cholecystoduodenal Fistula,Colovesical Fistula,Enterocutaneous Fistula,Fistula, Cholecystoduodenal,Fistula, Colovesical,Fistula, Enterocutaneous,Fistula, Intestinal
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012003 Rectal Fistula An abnormal anatomical passage connecting the RECTUM to the outside, with an orifice at the site of drainage. Anal Fistula,Fistula, Rectal
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003424 Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients. Colitis, Granulomatous,Enteritis, Granulomatous,Enteritis, Regional,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,Crohn's Disease,Crohn's Enteritis,Inflammatory Bowel Disease 1,Regional Enteritis,Crohns Disease,Granulomatous Colitis,Granulomatous Enteritis,Regional Ileitides,Regional Ileitis,Terminal Ileitis
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug

Related Publications

Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease.
August 2004, Revista espanola de enfermedades digestivas,
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Infliximab in fistulizing Crohn's disease.
December 2006, Gastroenterology clinics of North America,
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
April 2005, Gastroenterology,
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
January 2006, Digestive diseases (Basel, Switzerland),
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Maintenance infliximab for Crohn's disease.
November 2002, Lancet (London, England),
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
[Anorectal adenocarcinoma after Infliximab treatment for fistulizing Crohn's disease].
January 2017, The Pan African medical journal,
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Maintenance therapy versus episodic therapy with infliximab for Crohn's disease.
December 2004, Nature clinical practice. Gastroenterology & hepatology,
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn's disease.
November 2015, Future science OA,
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
Incorrect cost of infliximab in fistulizing Crohn's disease.
August 2004, Gastroenterology,
Bruce E Sands, and Frank H Anderson, and Charles N Bernstein, and William Y Chey, and Brian G Feagan, and Richard N Fedorak, and Michael A Kamm, and Joshua R Korzenik, and Bret A Lashner, and Jane E Onken, and Daniel Rachmilewitz, and Paul Rutgeerts, and Gary Wild, and Douglas C Wolf, and Paul A Marsters, and Suzanne B Travers, and Marion A Blank, and Sander J van Deventer
The management of fistulizing oral Crohn's disease with infliximab.
August 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,
Copied contents to your clipboard!